Home
Random
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
National Graphite Corp.
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Summary == National Graphite Corp., through its subsidiary, Biotech Development Corp., operates as a biopharmaceutical risk/cost-sharing company. The company collaborates with clinical stage companies that develop new biological entities or new therapeutically platforms for the treatment of various diseases, rare diseases, and diseases with unmet needs. It is developing a drug candidate called ELAFIN, which is a human identic protein for the treatment of postoperative inflammatory complications. National Graphite Corp. has a collaboration agreement with Proteo Inc. for developing ELAFIN. The company was formerly known as Lucky Boy Silver Corporation and changed its name to National Graphite Corp. in May 2012. National Graphite Corp. was founded in 2006 and is based in Duesseldorf, Germany. __INDEX__
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
